Collaborations

Partnering to advance groundbreaking programs in precision oncology

We are committed to partnering with the best and brightness minds in academia, biotechnology and pharma to advance programs in targeted/precision oncology. We partner with teams that share our vision to advance promising programs in potentially lethal diseases where the unmet need remains frustratingly high.

We are actively seeking opportunities to collaborate in any of the following areas:

• Precision oncology programs across solid tumors
• Neuro-oncology programs that select for genetically defined tumors
• Novel mechanisms of action; either first-in-class or potentially best-in-class
• Both pre-clinical and clinical stage assets

The management team at Chimerix has substantial experience in oncology drug development, manufacturing scale up and global regulatory expertise to accelerate precision oncology programs to approval. For more information about how we might work together, please contact Tom Riga, COO and CCO, at [email protected].

Key benefits of collaborating with Chimerix include:

• Strong culture of execution
• Extensive clinical development and regulatory experience
• Creativity in constructing partnerships
• Commitment to professional alliance management
• Track record of pioneering novel therapeutic targets for molecularly-defined diseases

Tom Riga, Chief Operating and Commercial Officer

“At Chimerix, our goal is to have a profound impact on cancer patients who have a high unmet medical need. Establishing productive partnerships with collaborators across the globe is a key driver in finding the right innovation to fight this elusive and complex disease. We have a long history of diverse partnerships across large pharmaceutical companies, smaller biotechs, geographic partnerships, government agencies and academic research institutions. Our approach to these relationships is guided by simple, yet direct principles:  we invest wisely, operate with high integrity, impart a sense of urgency and are honest about where the data lead us.”

Ongoing Strategic Transactions and Collaborations